Technical strength — GSK trades around GBX 1,806 despite muted daily pullback

Traders Union
All News
Financial News
GSK slides 0.44% today amid resistance

Highlights

GSK continued its share buyback program, repurchasing approximately 10.48 million shares, bringing its total treasury shares to 236,113,577, or 5.79% of voting rights.
BNP Paribas SA executed the latest buybacks, with two specific purchases of 170,000 and 170,733 shares now held as GSK treasury shares.
GSK is entangled in a lawsuit filed by AnaptysBio against Tesaro over an alleged contract breach, potentially impacting its pharmaceutical operations.

Capital structure shifts as buybacks and litigation drive flows

GSK has continued its share buyback program, recently repurchasing about 10.48 million shares and holding a total of 236,113,577 treasury shares, representing nearly 5.79% of voting rights and impacting its capital structure. BNP Paribas SA conducted the latest transactions, with individual purchases of 170,000 and 170,733 shares now held as treasury shares. The company is also involved in a lawsuit filed by AnaptysBio against Tesaro over an alleged contract breach involving GSK, and maintains a significant global pharmaceutical presence through its vaccines and specialty treatments.

Momentum divergence emerges as intraday selling tests bullish trend

The current price of GSK (GBX 1,806.00) sits above the MA-20 (GBX 1,788.50), MA-50 (GBX 1,674.55), and MA-200 (GBX 1,496.48), confirming a strong bullish structure in the short, medium, and long term. Immediate dynamic support is seen at the Ichimoku Kijun level (GBX 1,713.25), while the MA-50 (GBX 1,674.55) serves as further support if required. Momentum signals remain generally positive: the MACD shows Strong Buy and the ADX (26.04) signals a healthy bullish trend, although the daily price is down 0.44% with GBX 8.00 lost since the previous close. Oscillator readings present mixed signals — RSI (65.05) and CCI (119.13) both indicate conditions near overbought, the Stoch RSI is neutral, and BBP (33.98, Overbought) suggests buyers still dominate intraday, although strength may be waning. There was no notable gap at the open, with the price now trading toward the lower end of today’s range (GBX 1,802–1,812), on low volatility and showing some pressure after the open, highlighting a divergence between the strong broader trend and weaker intraday momentum.

Upside favored as weekly signals converge on limited downside

For the coming 5 trading days, GSK is expected to trade between GBX 1,780 and GBX 1,850 based on typical weekly volatility and the prevailing uptrend. The probability of an upward move is very high (more than 80%), reflecting unanimous Buy signals from major weekly indicators, making a decline less likely. In the baseline scenario, the price holds in a sideways corridor within this range; a bullish scenario would see GSK break above resistance near GBX 1,850, while a bearish scenario involves a slip below support at GBX 1,780, though this is currently the least likely outcome.

Viktoras Karapetjanc, expert at Traders Union, sees continued strength in GSK, supported by its robust share buyback program and a solid bullish trend above all key moving averages. He believes institutional demand and positive momentum indicators outweigh short-term weakness and news of legal risks. Despite minor intraday pullback, Karapetjanc remains highly optimistic given the global fundamentals and strong capital structure. In his words: "I expect GSK to keep outperforming in the coming days, with upside potential still intact as long as key support levels hold."

Previously it was noted that GSK continued its share buyback activity and established a new partnership to advance tuberculosis treatment. The technical outlook described overbought momentum alongside robust trend based on market indicators.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.